Skyviews Life Science

One.bio is an emerging biotechnology company spun out from UC Davis, specializing in the development of naturally-derived oligosaccharides for food, agriculture, and biopharmaceutical applications. Utilizing proprietary technology, the company creates novel oligosaccharides from natural products aimed at positively influencing the microbiome and enhancing immune function. One.bio's innovative ingredients provide clients with access to prebiotics and therapies that support both human and animal health, positioning the company as a significant player in the fields of nutrition and longevity.

Vedanta Biosciences, Inc. is a clinical-stage microbiome company based in Cambridge, Massachusetts, focusing on the development of therapies for immune-mediated diseases. Established in 2010, the company specializes in creating immunotherapies utilizing human microbiome-derived bacteria. Its innovative platform includes a collection of defined bacterial consortia, proprietary assays for selecting effective strains, and extensive datasets from human interventional studies. Vedanta Biosciences also possesses capabilities for cGMP-compliant manufacturing, allowing for the production of live bacterial therapies in powder form. This enables healthcare providers to administer oral treatments aimed at addressing autoimmune and inflammatory diseases efficiently, potentially pioneering a new category of therapies based on the human microbiome.

Volumina Medical SA is a Swiss company specializing in the development, manufacturing, and commercialization of advanced tissue reconstruction technologies tailored for the reconstructive and plastic surgery markets. The company focuses on tissue engineering, creating injectable 3D scaffolds that facilitate the reconstruction of lost soft tissue volumes due to tumor ablation, disease, trauma, or aesthetic needs. These innovative scaffolds can be administered through thin cannulas, which helps reduce both intervention and recovery times for patients, addressing the challenges associated with the natural repair of three-dimensional soft tissues.

Tropic Biosciences UK Ltd, established in 2016 and based in Norwich, is a biotechnology company specializing in the development of commercial tropical crops. It employs advanced plant breeding and non-GMO gene editing techniques to create high-performing varieties, catering primarily to the coffee and banana industries. The company's mission is to promote grower wellbeing, consumer health, and sustainable environmental practices through its innovative, non-GMO methods, which significantly accelerate the breeding process to meet growing food demands and local community needs.

One.bio is an emerging biotechnology company spun out from UC Davis, specializing in the development of naturally-derived oligosaccharides for food, agriculture, and biopharmaceutical applications. Utilizing proprietary technology, the company creates novel oligosaccharides from natural products aimed at positively influencing the microbiome and enhancing immune function. One.bio's innovative ingredients provide clients with access to prebiotics and therapies that support both human and animal health, positioning the company as a significant player in the fields of nutrition and longevity.

Vedanta Biosciences, Inc. is a clinical-stage microbiome company based in Cambridge, Massachusetts, focusing on the development of therapies for immune-mediated diseases. Established in 2010, the company specializes in creating immunotherapies utilizing human microbiome-derived bacteria. Its innovative platform includes a collection of defined bacterial consortia, proprietary assays for selecting effective strains, and extensive datasets from human interventional studies. Vedanta Biosciences also possesses capabilities for cGMP-compliant manufacturing, allowing for the production of live bacterial therapies in powder form. This enables healthcare providers to administer oral treatments aimed at addressing autoimmune and inflammatory diseases efficiently, potentially pioneering a new category of therapies based on the human microbiome.

Aleph Farms Limited is an innovative food technology company based in Ashdod, Israel, specializing in cellular agriculture to produce clean meat. Founded in 2017, Aleph Farms focuses on sustainable food production by developing methods to grow animal products directly from non-genetically modified animal cells, utilizing proprietary three-dimensional bioprinting technologies. The company made significant strides in the industry by unveiling the world's first cultivated thin-cut steak in 2018, followed by the first cultivated ribeye steak in 2021 and cultivated collagen in 2022. Under its product brand Aleph Cuts, its inaugural offering, the Petit Steak, is crafted from non-modified cells sourced from a premium Angus cow, allowing production without animal slaughter. Aleph Farms has garnered recognition for its commitment to climate leadership, including a net zero pledge made in 2020, earning accolades from prominent organizations like the World Economic Forum and the United Nations.

Aleph Farms Limited is an innovative food technology company based in Ashdod, Israel, specializing in cellular agriculture to produce clean meat. Founded in 2017, Aleph Farms focuses on sustainable food production by developing methods to grow animal products directly from non-genetically modified animal cells, utilizing proprietary three-dimensional bioprinting technologies. The company made significant strides in the industry by unveiling the world's first cultivated thin-cut steak in 2018, followed by the first cultivated ribeye steak in 2021 and cultivated collagen in 2022. Under its product brand Aleph Cuts, its inaugural offering, the Petit Steak, is crafted from non-modified cells sourced from a premium Angus cow, allowing production without animal slaughter. Aleph Farms has garnered recognition for its commitment to climate leadership, including a net zero pledge made in 2020, earning accolades from prominent organizations like the World Economic Forum and the United Nations.

Cellares Corporation, founded in 2019 and based in South San Francisco, California, specializes in the development of cell therapies for cancer treatment. The company addresses significant manufacturing challenges associated with these therapies, which are often produced on a per-patient basis, leading to high costs and limited availability. Cellares is pioneering the Cell Shuttle, an automated, closed end-to-end manufacturing solution designed to enhance the scalability and efficiency of cell therapy production. This innovative system allows for the simultaneous production of ten times more patient doses compared to traditional manual methods, while also reducing process failure rates by three-fold and lowering manufacturing costs by up to 70 percent. By providing flexible and scalable manufacturing options, Cellares aims to accelerate the delivery of life-saving therapies to patients in need and support the broader biopharmaceutical industry in meeting global demand for these treatments.

MIRAI FOODS is a cellular agriculture startup developing cultivated beef.

Ukko is a biotechnology company focused on enhancing the quality of life for individuals affected by food allergies and disorders. The company utilizes a computational engineering platform that employs artificial intelligence, immunology, and protein engineering to redesign food allergens into therapeutics that are both safe and effective. By creating a comprehensive, clinically validated map of the molecular structures associated with food allergies, Ukko reveals critical insights into the biological mechanisms governing human-food interactions. This innovative approach enables the development of new protein versions that do not provoke an immune response, providing a novel strategy for treating protein-based allergies.

Tropic Biosciences UK Ltd, established in 2016 and based in Norwich, is a biotechnology company specializing in the development of commercial tropical crops. It employs advanced plant breeding and non-GMO gene editing techniques to create high-performing varieties, catering primarily to the coffee and banana industries. The company's mission is to promote grower wellbeing, consumer health, and sustainable environmental practices through its innovative, non-GMO methods, which significantly accelerate the breeding process to meet growing food demands and local community needs.

One.bio is an emerging biotechnology company spun out from UC Davis, specializing in the development of naturally-derived oligosaccharides for food, agriculture, and biopharmaceutical applications. Utilizing proprietary technology, the company creates novel oligosaccharides from natural products aimed at positively influencing the microbiome and enhancing immune function. One.bio's innovative ingredients provide clients with access to prebiotics and therapies that support both human and animal health, positioning the company as a significant player in the fields of nutrition and longevity.

COMPASS Pathways is a mental health care company based in Cheshire, United Kingdom, with operations in the United States. The company is focused on developing innovative therapies for treatment-resistant depression (TRD) using its proprietary psilocybin formulation, COMP360. Currently undergoing Phase IIb clinical trials, COMP360 aims to provide a new treatment option for patients who have not responded to traditional depression therapies. COMPASS Pathways emphasizes the combination of psilocybin-assisted therapy with psychological support to enhance treatment efficacy. The company is committed to addressing the significant unmet needs in mental health care by advancing evidence-based solutions for those suffering from mental health challenges.